Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-6 (Cancelled)

Claim 7 (Previously presented): The method according to claim 96, which further comprises providing an air flow to encourage the deposition of the at least one fiber or fibrils on said support surface.

Claim 8 (Previously presented): The method according to claim 96, which further comprises regulating the temperature of a region where the liquid issues from the outlet to facilitate the formation of the at least one fiber or fibrils.

Claim 9 (Previously presented): The method according to claim 96, which comprises establishing the electric field by applying a high voltage to the support surface.

Claim 11 (Previously presented): The method according to claim 96, which further comprises using as the support surface a rotatable endless surface.

Claim 12 (Cancelled)

Claim 13 (Previously presented): The method according to claim 96, wherein said active ingredient is incorporated into the at least one fiber or fibrils.

Claim 14 (Currently amended): The method according to claim 96, which further comprises forming the at least one fiber or fibrils with a core containing the at least one active ingredient.

Claim 15 (Previously presented): The method according to claim 96, wherein said active ingredient is a medicament for use in the treatment of a human or animal.

Claim 16 – 34 (Cancelled)

Serial No. 10/018,160

Claim 35 (Previously presented): The method according to claim 96, wherein the individual tablets are formed using a cutting means.

Claim 36 (Previously presented): The method according to claim 96, wherein said cutting means is a pair of reciprocating knives.

Claim 37 - 39 (Cancelled)

Claim 40 (Previously presented): The method according to claim 96, wherein said active ingredient is coated on the fibers.

Claim 41 (previously presented): The method according to claim 96, wherein said carrier liquid consists essentially of a hydrophilic solution of gelatin dissolved in a mixture of water and ethanol, wherein a sweetener is incorporated into said fibers.

Claim 42 (Previously presented): The method according to claim 41, wherein the sweetener is saccharine.

Claims 43 - 58 (Cancelled)

Claim 59 (Previously presented): The method according to claim 96, wherein the formation of a plurality of individual tablets occurs during the deposition of the at least one fiber or fibril onto the support surface.

Claim 60 (Previously presented): The method according to claim 59, wherein said fiber or fibril at least partially coats said active ingredient within said fiber web or mat.

Claim 71 (Currently amended): A method of manufacturing a biodissolvable <u>rapid</u> dissolving tablet <u>suitable for buccal delivery of an active agent</u> containing one or more active medicaments, comprising the steps of

(1) supplying a biologically acceptable carrier liquid comprising a solution of a biologically acceptable polymer in a mixture of water and ethanol, wherein said water and ethanol are present in said carrier liquid at a ratio of from

- about 1:0.8 to about 1:1.5, through a first supply tube to an outlet of said first supply tube;
- (2) establishing an electric field between the outlet of said first supply tube and a support surface that is spaced from the outlet to cause liquid issuing from the outlet to form at least one fiber or fibrils of said carrier liquid;
- (3) causing said fibers to deposit onto the support surface to form a fibrous porous web or mat;
- (4) supplying a biologically acceptable carrier liquid <u>comprising containing</u> an active medicament through a second supply tube to an outlet of said second supply tube;
- (5) applying a charge to said carrier liquid of Step 4 opposite the charge of said first electric field of Step 2 to form a layer of fibers comprising containing said active ingredient on top of the layer of fibers from Step 3;
- (6) repeating Steps 1-3 so as to deposit a layer of fibers on the surface of the layer of fibers of active ingredient from Step 5; and
- (7) forming a plurality of individual tablets from the layers of sandwich of fiber web or mat, fibers of active ingredient and fiber web or mat; and

wherein said biologically acceptable carrier liquid consists of a solution of a biologically acceptable, hydrophilic polymer dissolved in a solvent for said polymer; and wherein the individual tablets are capable of rapid dissolution suitable for buccal delivery being rapidly and completely dissolve on moist surfaces.

Claim 72 (cancelled): The method according to claim 71 wherein said carrier liquid is a solution of a biologically acceptable polymer in a mixture of water and ethanol.

Claim 73 (Previously presented): The method according to claim 72 wherein said biologically acceptable polymer is selected from the group consisting of gelatin, polyvinyl pyrrolidone, polyvinyl alcohol having a molecular weight of from about 100,000 to about 130,000, vinylpyrrolidone/vinylacetate copolymer, vinylpyrrolidone/vinylimidazole copolymer, poly-sucrose, starch, cellulose, and sugars.

Claim 74 (Previously presented): The method according to claim 73 wherein said biologically acceptable polymer is selected from the group consisting of gelatin, polyvinyl pyrrolidone, vinylpyrrolidone/vinylacetate copolymer, vinylpyrrolidone/vinylimidazole copolymer, and polyvinyl alcohol having a molecular weight of from about 100,000 to about 130,000.

Claim 75 (Previously presented): The method according to claim 74 wherein said biologically acceptable polymer is selected from the group consisting of gelatin, polyvinyl pyrrolidone, and vinylpyrrolidone/vinylacetate copolymer.

Claim 76 (Previously presented): The method according to claim 75 wherein said biologically acceptable polymer is vinylpyrrolidone/vinylacetate copolymer.

Claim 77 (Previously presented): The method according to claim 75 wherein said biologically acceptable polymer is gelatin.

Claim 78 -79 (cancelled)

Claim 80 (Previously presented): The method according to claim 79 wherein said biologically acceptable polymer is selected from the group consisting of gelatin, polyvinyl pyrrolidone, polyvinyl alcohol, vinylpyrrolidone/vinylacetate copolymer, polysucrose, starch, cellulose, sugars, and confectionery materials.

Claim 81 (Previously presented): The method according to claim 80 wherein said biologically acceptable polymer is selected from the group consisting of gelatin, polyvinyl pyrrolidone, vinylpyrrolidone/vinylacetate copolymer and polyvinyl alcohol.

Claim 82 (Previously presented): The method according to claim 81 wherein said biologically acceptable polymer is polyvinyl pyrrolidone.

Claim 83 (Previously presented): The method according to claim 82 wherein said biologically acceptable polymer is vinylpyrrolidone/vinylacetate copolymer.

Serial No. 10/018,160

Claim 84 (Previously presented): The method according to claim 83 wherein said biologically acceptable polymer is gelatin.

Claim 85 (cancelled)

Claim 86 (Previously presented): The method according to claim 96 wherein said active ingredient is a medicament for a human or an animal.

Claim 87 (Previously presented): The method according to claim 86 wherein said active ingredient is a medicament for an animal.

Claim 88 (Previously presented): The method according to claim 86 wherein said active ingredient is a medicament for a human.

Claim 89 (Previously presented): The method according to claim 86 wherein said active ingredient is a medicament selected from the group comprising a drug, vaccine, enzyme, or diagnostic agent.

Claim 90 (Previously presented): The method according to claim 96 wherein said active ingredient is a confectionary material.

Claim 91 (Previously presented): The method according to claim 71 wherein said active ingredient is a medicament for a human or an animal.

Claim 92 (Previously presented): The method according to claim 91 wherein said active ingredient is a medicament for an animal.

Claim 93 (Previously presented): The method according to claim 90 wherein said active ingredient is a medicament for a human.

Claim 94 (Previously presented): The method according to claim 91 wherein said active ingredient is a medicament selected from the group consisting of a drug, vaccine, enzyme or diagnostic agent.

Claim 95 (Cancelled)

Serial No. 10/018,160

Claim 96 (Currently Amended): A method of manufacturing <u>rapidly dissolvable</u> biodissolvable tablets <u>suitable for buccal delivery of an active agent containing one or more active ingredients, comprising the steps of:</u>

- supplying a biologically acceptable carrier liquid consisting essentially of 5 grams of fish gelatin in a solvent consisting of from about 7 ml to about 9 ml of water and from about 10 ml to about 11 ml of ethanol comprising containing one or more active ingredients dissolved or suspended therein and a flavoring agent, through a supply tube to an outlet of the supply tube;
- (ii) establishing an electric field between the outlet and a support surface that is spaced from the outlet to cause liquid issuing from the outlet to form at least one fiber or fibrils of said carrier liquid;
- (iii) causing said fibers to deposit onto the support surface to form a fibrous porous web or mat; and
- (iv) forming a plurality of individual tablets from the web or mat, the individual tablets capable of rapid dissolution for buccal delivery being configured to rapidly and completely dissolve on moist surfaces; wherein said biologically acceptable carrier liquid consists of a solution of a biologically acceptable, hydrophilic polymer dissolved in a solvent for said polymer.

Claim 97 (cancelled)

Claim 98 (cancelled)